CABA Stock Risk & Deep Value Analysis

Cabaletta Bio Inc

DVR Score

6.5

out of 10

Solid Pick

The Bottom Line on CABA

We analyzed Cabaletta Bio Inc using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran CABA through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.

Updated May 3, 2026•Run Fresh Analysis →

📈CABA Performance Overview3yr weekly

📊

Unlock CABA Performance Chart

See 3 years of price history, quarterly revenue trends, and DVR score changes

Weekly adjusted close · Quarterly revenue & EPS · DVR score history

CABA Stock Risk Analysis

Overall Risk

Aggressive

Financial Risk

High

Market Risk

Medium

CABA Deep Value Analysis

Cabaletta Bio presents a compelling, albeit significantly riskier, high-reward opportunity. Its precision cell therapy platform targeting autoimmune diseases, particularly CABA-201, addresses vast unmet medical needs with a differentiated approach. Recent progress in clinical trials and a commercial manufacturing deal for rese-cel demonstrate strong operational execution. However, a material shift in its financial outlook, specifically the 'going-concern doubt beyond Q4 2026' and the proposed doubling of authorized shares for significant dilution, introduces severe immediate financial risk. While the clinical upside remains substantial, the funding challenge and potential for massive dilution overshadow the promising pipeline, necessitating a substantial downward adjustment in its overall rating.

CABA Red Flags & Warning Signs

Premium

⚠
Unfavorable clinical data from ASGCT 2026 or subsequent trials
⚠
Failure to secure adequate financing or highly dilutive financing terms
⚠
Regulatory setbacks or delays in drug development

Unlock CABA Red Flags & Risk Warnings

Premium members see every risk event we found.

📈

Unlock the full report

Create a free account to see the DVR score, risk flags, and AI analysis.

🔥 New Member Exclusive

Unlock everything for $47/yr

$79/yrSave 41%

✓ Catalysts, bull case, moat & red flags
✓ Unlimited stock analyses + alerts
✓ Full database, search & portfolio (50 stocks)

Get Premium — $47/yr

7-day money back · Cancel anytime

CABA Financial Health Metrics

Market Cap

$327.29M

P/E Ratio

-1.40

Debt-to-Equity

0.21

Beta (Volatility)

3.22

Earnings Per Share

$-2.28

CABA Competitive Moat Analysis

Premium

Moat Rating

Narrow

Moat Trend

Expanding

Moat Sources

2 Identified

Intangible Assets/IP (proprietary cell therapy technology and clinical data)Switching Costs (for both patients and prescribers, once an effective therapy is established and integrated into treatment protocols)

The moat, primarily based on proprietary technology and clinical differentiation, is currently expanding as CABA generates promising clinical data. Its durability will hinge on successful late-stage trials, regulatory approvals, and the ability to scale manufacturing and commercialization ahead of competitors.

CABA Competitive Moat Analysis

Premium unlocks moat rating, sources & durability.

CABA Catalysts & Growth Drivers

Near-Term (0-6 months)

•New rese-cel data presentation at ASGCT 2026 (May 11-15)
•Q1 2026 Earnings (Expected May 14, 2026)
•Resolution of 'going concern' through financing announcement (likely Q2/Q3 2026)

Medium-Term (6-18 months)

•Further Phase 1/2 clinical data readouts for CABA-201
•Advancement of manufacturing partnership with Cellares
•Potential strategic partnerships or collaborations

Long-Term (18+ months)

•Initiation of pivotal clinical trials for lead assets
•Regulatory filings and potential market approval for rese-cel or CABA-201
•Expansion of pipeline into additional autoimmune indications

Catalysts & Growth Drivers

Upgrade to Premium to see catalysts

CABA Bull Case: What Could Go Right

✓
Positive clinical data readouts for CABA-201 and rese-cel, particularly on efficacy and safety.
✓
Terms of the next financing round: amount raised, share price, and resulting dilution percentage.
✓
Updates on cash runway and progress towards commercialization readiness.

Bull Case Analysis

See what could go right with Premium

🔔

Never miss a move on CABA

Create a free account to set price alerts and get notified on Telegram when CABA hits your targets.

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.

Analyze Any Stock →View Top 100 Deep Value Stocks →

FAQ

What is the DVR Score for Cabaletta Bio Inc (CABA)?

As of May 3, 2026, Cabaletta Bio Inc has a DVR Score of 6.5 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.

What is the market capitalization of Cabaletta Bio Inc?

Cabaletta Bio Inc's market capitalization is approximately $327.3M..

What is the risk level for CABA stock?

Our analysis rates Cabaletta Bio Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.

What is the P/E ratio of CABA?

Cabaletta Bio Inc currently has a price-to-earnings (P/E) ratio of -1.4. This is below the market average, which could indicate the stock is undervalued or facing headwinds.

How often is the CABA DVR analysis updated?

Our AI-powered analysis of Cabaletta Bio Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on May 3, 2026.

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.